dronabinol has been researched along with Tics in 7 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (42.86) | 29.6817 |
2010's | 2 (28.57) | 24.3611 |
2020's | 2 (28.57) | 2.80 |
Authors | Studies |
---|---|
Aguirre Dávila, L; Guizzaro, L; Koch, A; Lasch, F; Müller-Vahl, K | 1 |
Lobsien, E; Schwittay, MA; Steinbrecher, A | 1 |
Jakubovski, E; Müller-Vahl, K | 1 |
Bird, R; Evans, L; Trainor, D | 1 |
Daldrup, T; Emrich, HM; Kolbe, H; Müller-Vahl, KR; Prevedel, H; Schneider, U; Theloe, K | 1 |
Burket, JA; Connor, JM; Deutsch, SI; Fox, FJ; Murphy, ME; Rosse, RB | 1 |
Daldrup, T; Emrich, HM; Jöbges, M; Koblenz, A; Kolbe, H; Müller-Vahl, KR; Schneider, U | 1 |
3 trial(s) available for dronabinol and Tics
Article | Year |
---|---|
Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial.
Topics: Adolescent; Adult; Double-Blind Method; Dronabinol; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Receptors, Cannabinoid; Receptors, Drug; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome | 2003 |
Current status of cannabis treatment of multiple sclerosis with an illustrative case presentation of a patient with MS, complex vocal tics, paroxysmal dystonia, and marijuana dependence treated with dronabinol.
Topics: Adult; Cannabis; Dronabinol; Female; Hallucinogens; Humans; Male; Marijuana Abuse; Multiple Sclerosis; Nocturnal Paroxysmal Dystonia; Phytotherapy; Tics | 2008 |
Treatment of Tourette's syndrome with Delta 9-tetrahydrocannabinol (THC): a randomized crossover trial.
Topics: Adolescent; Adult; Aged; Cross-Over Studies; Double-Blind Method; Dronabinol; Female; Humans; Male; Middle Aged; Pilot Projects; Psychiatric Status Rating Scales; Tics; Tourette Syndrome; Treatment Outcome | 2002 |
4 other study(ies) available for dronabinol and Tics
Article | Year |
---|---|
Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.
Topics: Cannabidiol; Computer Simulation; COVID-19; Data Interpretation, Statistical; Dronabinol; Drug Combinations; Endpoint Determination; Humans; Mental Health; Physical Distancing; Randomized Controlled Trials as Topic; Research Design; Sample Size; Severity of Illness Index; Tic Disorders; Tics; Time Factors; Tourette Syndrome; Treatment Outcome | 2021 |
Tic Reduction in Adult Onset Gilles De La Tourette Syndrome Using as Required Nabiximols Spray.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Humans; Male; Tics; Tourette Syndrome | 2021 |
Speechlessness in Gilles de la Tourette Syndrome: Cannabis-Based Medicines Improve Severe Vocal Blocking Tics in Two Patients.
Topics: Adolescent; Adult; Cannabinoid Receptor Agonists; Dronabinol; Humans; Male; Medical Marijuana; Severity of Illness Index; Tics; Tourette Syndrome; Young Adult | 2017 |
Severe motor and vocal tics controlled with Sativex®.
Topics: Adult; Cannabidiol; Dronabinol; Drug Combinations; Humans; Male; Psychiatric Status Rating Scales; Reproducibility of Results; Severity of Illness Index; Tics; Tourette Syndrome; Treatment Outcome; Videotape Recording | 2016 |